WO2014011895A3 - Sels d'acides à solubilité élevée, formes posologiques intraveineuses, apport complémentaire nutritionnel et leurs procédés d'utilisation - Google Patents

Sels d'acides à solubilité élevée, formes posologiques intraveineuses, apport complémentaire nutritionnel et leurs procédés d'utilisation Download PDF

Info

Publication number
WO2014011895A3
WO2014011895A3 PCT/US2013/050100 US2013050100W WO2014011895A3 WO 2014011895 A3 WO2014011895 A3 WO 2014011895A3 US 2013050100 W US2013050100 W US 2013050100W WO 2014011895 A3 WO2014011895 A3 WO 2014011895A3
Authority
WO
WIPO (PCT)
Prior art keywords
acid salts
dosage forms
methods
intravenous dosage
high solubility
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/050100
Other languages
English (en)
Other versions
WO2014011895A2 (fr
Inventor
Banavara L. Mylari
Frank C. SCIAVOLINO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thetis Pharmaceuticals LLC
Original Assignee
Thetis Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thetis Pharmaceuticals LLC filed Critical Thetis Pharmaceuticals LLC
Publication of WO2014011895A2 publication Critical patent/WO2014011895A2/fr
Publication of WO2014011895A3 publication Critical patent/WO2014011895A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des sels d'acide gras ω-3 hautement solubles et hautement biodisponibles. Ces sels d'acide gras ont une biodisponibilité élevée lorsqu'ils sont administrés par voie orale. Ils sont également utilisés pour des formes posologiques intraveineuses à concentration relativement élevée qui peuvent être utilisées pour le traitement de la défibrillation atriale. Ces sels d'acide gras peuvent également être utilisés pour supplémenter un aliment, une boisson et des produits nutraceutiques par des acides gras polyinsaturés ω-3.
PCT/US2013/050100 2012-07-11 2013-07-11 Sels d'acides à solubilité élevée, formes posologiques intraveineuses, apport complémentaire nutritionnel et leurs procédés d'utilisation Ceased WO2014011895A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261670262P 2012-07-11 2012-07-11
US61/670,262 2012-07-11

Publications (2)

Publication Number Publication Date
WO2014011895A2 WO2014011895A2 (fr) 2014-01-16
WO2014011895A3 true WO2014011895A3 (fr) 2014-03-13

Family

ID=49916688

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/050100 Ceased WO2014011895A2 (fr) 2012-07-11 2013-07-11 Sels d'acides à solubilité élevée, formes posologiques intraveineuses, apport complémentaire nutritionnel et leurs procédés d'utilisation

Country Status (1)

Country Link
WO (1) WO2014011895A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9999626B2 (en) 2014-06-18 2018-06-19 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of active agents
US10130719B2 (en) 2016-06-03 2018-11-20 Thetis Pharmaceuticals Llc Compositions and methods relating to salts of specialized pro-resolving mediators

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9505709B2 (en) 2014-05-05 2016-11-29 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
PE20171083A1 (es) * 2014-12-23 2017-08-03 Evonik Degussa Gmbh Proceso para aumentar la estabilidad de una composicion que comprende acidos grasos omega-3 poliinsaturados
WO2017079391A1 (fr) * 2015-11-04 2017-05-11 Thetis Pharmaceuticals Llc Sels d'acides aminés d'acides gras saturés
EP3648748A1 (fr) 2017-07-06 2020-05-13 Evonik Operations GmbH Forme posologique solide à enrobage entérique comprenant des sels d'acides aminés d'acides gras oméga-3
US11622952B2 (en) 2017-08-15 2023-04-11 Evonik Operations Gmbh Tablets with high active ingredient content of omega-3 fatty acid amino acid salts
WO2020109480A1 (fr) * 2018-11-30 2020-06-04 Evonik Operations Gmbh Préparation destinée à être utilisée pour accroître la formation d'un ou plusieurs médiateurs lipidiques pro-résolution spécialisés (spm)
US20220233487A1 (en) 2019-05-06 2022-07-28 Evonik Operations Gmbh Preparation for use in weight management comprising omega-3 fatty acid salts and basic amino acids
EP4009956A1 (fr) 2019-08-08 2022-06-15 Evonik Operations GmbH Procédé de diffusion en continu pour la production de sels d'acides gras polyinsaturés
US20220287345A1 (en) 2019-08-08 2022-09-15 Evonik Operations Gmbh Solubility enhancement of poorly soluble actives
US20230149336A1 (en) * 2020-04-01 2023-05-18 Evonik Operations Gmbh Preparation for use as antioxidant
EP4125437A1 (fr) * 2020-04-01 2023-02-08 Evonik Operations GmbH Préparation destinée à être utilisée en tant que vasorelaxeur

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090221705A1 (en) * 2006-02-07 2009-09-03 Pal Rongved Omega 3
US7619002B2 (en) * 2001-11-12 2009-11-17 Pro Aparts Investimentos E Consultoria LDA. AV. Arriaga Use of polyunsaturated fatty acids for the primary prevention of major cardiovascular events
US20110200645A1 (en) * 2010-02-18 2011-08-18 Martek Biosciences Corporation DHA Free Fatty Acid Emulsions
US20120121698A1 (en) * 2009-04-29 2012-05-17 Amarin Pharma, Inc. Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7619002B2 (en) * 2001-11-12 2009-11-17 Pro Aparts Investimentos E Consultoria LDA. AV. Arriaga Use of polyunsaturated fatty acids for the primary prevention of major cardiovascular events
US20090221705A1 (en) * 2006-02-07 2009-09-03 Pal Rongved Omega 3
US20120121698A1 (en) * 2009-04-29 2012-05-17 Amarin Pharma, Inc. Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
US20110200645A1 (en) * 2010-02-18 2011-08-18 Martek Biosciences Corporation DHA Free Fatty Acid Emulsions

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9999626B2 (en) 2014-06-18 2018-06-19 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of active agents
US10130719B2 (en) 2016-06-03 2018-11-20 Thetis Pharmaceuticals Llc Compositions and methods relating to salts of specialized pro-resolving mediators
US11135298B2 (en) 2016-06-03 2021-10-05 Thetis Pharmaceuticals Llc Compositions and methods relating to salts of specialized pro-resolving mediators
US11191840B2 (en) 2016-06-03 2021-12-07 Thetis Pharmaceuticals Llc Compositions and methods relating to salts of specialized pro-resolving mediators
US11925688B2 (en) 2016-06-03 2024-03-12 Thetis Pharmaceuticals Llc Compositions and methods relating to salts of specialized pro-resolving mediators

Also Published As

Publication number Publication date
WO2014011895A2 (fr) 2014-01-16

Similar Documents

Publication Publication Date Title
Kim et al. α-Linolenic acid: Nutraceutical, pharmacological and toxicological evaluation
HK1206248A1 (en) Compositions of statins and omega-3 fatty acids
MY189576A (en) Omega-3 fatty acid ester compositions
WO2013123139A8 (fr) Procédés, compositions et dispositifs pour satisfaire aux besoins alimentaires en acides gras
WO2013150386A3 (fr) Compositions comprenant des acides gras oméga-3 et de la vitamine d destinées à lutter contre l'acné vulgaire et/ou l'eczéma, et méthodes et utilisations associées
WO2014074552A3 (fr) Compositions et procédés pour diminuer les triglycérides sans augmenter les taux de ldl-c chez un sujet traité en même temps par la statine
HK1204271A1 (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
HK1204272A1 (en) Methods of treating pediatric metabolic syndrome
WO2013049519A3 (fr) Compositions, kits et méthodes de supplémentation alimentaire avec des acides gras à douze atomes de carbone et des acylglycérols à douze atomes de carbone
MY186188A (en) Nutritional phytonutrient compositions
WO2011097276A8 (fr) Procédés et compositions pour traiter l'arthrite par de l'acide docosahexaénoïque
HK1198515A1 (en) Fatty acid compositions
WO2012094598A3 (fr) Compositions pharmaceutiques de fer pour administration orale
WO2012085671A3 (fr) Antioxydants dans la poudre et les comprimés à base d'huiles de poissons
PH12018500036A1 (en) Nutritional compositions containing phosphatidylethanolamine, sphingomyelin and docosahexaenoic acid
WO2014165190A3 (fr) Compositions comprenant de l'acide docosapentaénoïque et procédés d'utilisation
PH12015502517B1 (en) Compositions and methods for nutrient delivery
WO2014008465A3 (fr) Potentialisation d'un traitement antibiotique avec un complexe protéine-lipide
PH12013500736A1 (en) Compositions and methods for nutrient delivery
WO2014008379A3 (fr) Formes salines diamine et méglumine d'acides gras
JP2017536367A5 (fr)
Doka et al. Nutritional profile and radical scavenging capacity of tubers of two Dioscorea species
JP2014521348A5 (fr)
Kiefer Nutrients for Macular Degeneration: An RCT
HK1176524A1 (zh) 包含单酸甘油酯及脂肪酸之营养品

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 13816382

Country of ref document: EP

Kind code of ref document: A2